Dynamics of oxidative status in patients with paroxysmal atrial fibrillation by Negreva, Mariya et al.
Scripta Scientifica Medica, vol. 46, No 3, 2014, pp. 33-41
Copyright © Medical University of Varna   33
ORIGINAL ARTICLES
DYNAMICS OF OXIDATIVE STATUS IN PATIENTS WITH 
PAROXYSMAL ATRIAL FIBRILLATION
1Mariya Negreva, 1Svetoslav Georgiev, 2Atanas Penev, 3Albena Alexandrova
1Department of Cardiology, Medical University of Varna, 
2Associate Professor, Department of Cardiology, Medical University of Varna, 
3Associate Professor, Laboratory of Free Radical Processes,  
Institute of Neurobiology, Bulgarian Academy of Science
Address for correspondence:  
Mariya Negreva
Department of Cardiology
Medical University of Varna
e-mail: mnegreva@abv.bg
Received: August 30, 2014
Accepted: September 10, 2014
INTRODUCTION
Atrial fibrillation (AF) is the most common ar-
rhythmia in clinical practice, affecting 1-2% of the 
total population (1). It is a significant public health 
ABSTRACT
INTRODUCTION: Studies have established oxidative disorders in persistent and permanent atrial fibril-
lation. Our aim was to investigate oxidative status still in the early hours of paroxysmal atrial fibrillation 
(PAF) and monitor its changes after sinus rhythm (SR) restoration.
MATERIAL AND METHODS: Levels of malondialdehyde and total glutathione were determined in plas-
ma (Pl-MDA; Pl-GSH) and erythrocytes (Er-MDA; Er-GSH) together with erythrocyte glutathione perox-
idase activity (GSH-Px) in 51 patients (59.84±1.6 years, 26 males). Markers were investigated upon hospi-
tal admission, 24 hours and 28 days after SR restoration. They were also determined in 52 healthy subjects 
(59.50±1.46 years, 26 males).
RESULTS: Mean AF duration prior to hospitalization was 8.14±0.76 hours. Upon admission, Pl-MDA and 
Er-MDA were significantly increased (p<0.05; p<0.001), while Pl-GSH, Er-GSH and GSH-Px - decreased 
(p<0.001). Twenty four hours after rhythm conversion, changes in Er-MDA (p<0.001), Pl-GSH, Er-GSH and 
GSH-Px (p<0.05) were retained. On the 28th day, there was no significant difference in any of the markers 
(p>0.05).
CONCLUSION: Disorder of oxidative status is detected in the early hours of  PAF, which persists after SR 
restoration. Oxidative balance is restored slowly with time. This specific dynamics of oxidative status is 
most likely related to AF clinical course, namely to its manifestation and recurrences.
Keywords: atrial fibrillation, malondialdehyde, glutathione, glutathione peroxidase, sinus rhythm
problem as its manifestation is associated with deteri-
orated quality of life, increased incidence of thrombo-
embolic accidents and increased risk of cardiovascu-
lar mortality (2-4). In spite of the considerable body of 
investigations, the mechanisms determining the clin-
ical course of arrhythmia are not fully clarified (5).
In recent years more and more evidence has 
been accumulated concerning the possible role of 
oxidative stress in the development of AF. The his-
tological studies have established oxidative chang-
es in the myocardium both by experimental models 
and in patients with AF (6-10). Increased levels of ox-
idative markers were measured in patients with per-
sistent and permanent AF (11-13). It was established 
34  Scripta Scientifica Medica, vol. 46, No 3, 2014, pp. 33-41
Copyright © Medical University of Varna
Dynamics of oxidative status in patients with paroxysmal atrial fibrillation
that these changes were due to the presence of the 
rhythm disorder (14,15). Changes in the gene expres-
sion profile were also proved (16). However, clinical 
in vivo studies lack, investigating oxidative status in 
the early hours of AF manifestation and following its 
changes after the restoration of sinus rhythm (SR). 
It is known that oxidative status depends si-
multaneously on the levels of oxidative processes 
and antioxidant defense system (17). Lipid biomole-
cules, polyunsaturated fatty acids, in particular, are 
extremely susceptive to the action of reactive oxygen 
species (ROS) (18). Therefore, the products of lipid 
peroxidation are frequently used biomarkers in the 
assessment of oxidative damages in vivo (19). One of 
the main products of secondary lipid decomposition 
is malondialdehyde (MDA) (20). This turns it into a 
common marker of the assessment of oxidative pro-
cesses in the human organism. 
An important component of the complex anti-
oxidant defense system of the organism is glutathi-
one (GSH). High electron-donating capacity in com-
bination with high intracellular concentration deter-
mines the considerable reduction power of GSH (21). 
In essence, it is a “key” nonenzyme antioxidant for 
the organism (22). Although it is relatively resistant 
to “spontaneous oxidation”, GSH can directly react 
with hydroxyl radicals and peroxynitrites and neu-
tralize them (23). Furthermore, it is an obligatory co-
factor of one of the major antioxidant enzymes glu-
tathione peroxidase (GSH-Px) (22). In its presence 
GSH-Px catalyzes the reduction of hydrogen perox-
ide and organic hydroperoxides to water or the corre-
sponding alcohols (24). The system GSH/GSH-Px is 
crucial for the condition of antioxidant defense sys-
tem in the human organism (22, 25-27).
All the above determined both the aim of our 
study and the investigated markers.
AIM
To study in dynamics the oxidative status of pa-
tients with paroxysmal atrial fibrillation (PAF) (ar-
rhythmia duration < 48 hours) by monitoring the 
plasma and erythrocyte levels of MDA (Pl-MDA; Er-
MDA) and total GSH (Pl-GSH; Er-GSH) as well as the 
activity of the enzyme GSH-Px in the erythocytes.
MATERIAL AND METHODS
1. Study population
The study was conducted at the Intensive 
Cardiac Care Unit of the First Clinic of Cardiology 
at University Hospital „St. Marina“ – Varna for the 
period from October 2010 to May 2012 following 
the approval of the Scientific Research Ethical 
Commission at the hospital and in accordance with 
the requirements of the Helsinki Declaration (28).
The participants were included in the study 
after having signed the informed consent form for 
participation.
For the purposes of the study, patients with 
PAF, only with a history of arrhythmia < 48 hours, 
were screened which could allow for an acute medi-
cation attempt to restore SR. Out of 338 patients, 259 
patients had to be excluded from the study (see ex-
clusion criteria). The criterion for the establishment 
of the duration of the rhythm disorder was the tak-
ing of a detailed history, in which the patients deter-
mined the onset of the AF episode according to the 
subjective feeling of “palpitation” continuing up to 
the moment of hospitalization. The electrocardio-
graphic investigations performed immediately after 
hospitalization and the monitoring were used as a 
confirmation of the diagnosis.
In order to restore SR, propafenone was admin-
istered in all the remaining 79 patients according to 
the established scheme, namely i.v. 2 mg/kg bolus, 
followed by infusion in a dose 0.0078 mg/kg/min for 
120 min. If the rhythm disorder persisted, the treat-
ment with propafenone continued р.о. in a dose 300 
mg three times at an interval of 8 hours (29,30). The 
total duration of the applied scheme for SR recovery 
with propafenone was maximum 24 hours, within 
which SR was registered in 56 of the participants in 
the study (31 male, 25 female). Until the end of the 
study (28 days after recovery of the rhythm) all the 
56 patients took p.o. propafenone 150 mg three times 
daily as maintenance dose. AF recurrences were not 
observed.
After having equalized the gender structure of 
the patients’ group, 51 patients (26 male и 25 female) 
of mean age 59.84±1.60 years (31-77 years) were se-
lected for the study.
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There are no literary data so far about the im-
pact of propafenone on the oxidative status of pa-
tients with AF. 
A control group was formed identical to the pa-
tients’ group in terms of the factors for which it is 
known that influence oxidative status, namely: gen-
der, age (in decades), body mass index (BMI), delete-
rious habits as well as in terms of accompanying dis-
eases and the treatment administered for them. Out 
of 169 screened healthy subjects (controls), 52 were 
selected for the study. The mean age of the controls 
was 59.50±1.46 years (30-76 years), males and females 
being of equal number – 26 (50%). The controls had 
no history or electrocardiographic evidence of AF.
The following exclusion criteria for the study 
participation were used:
1. Cardiovascular diseases, namely: ischaemic 
heart disease, chronic heart failure, resistent 
hypertension, implanted devices for the 
treatment of rhythm conductive disorders, 
imflammatory or congenital heart diseases, 
moderate or severe acquired valve diseases, 
cardiomyopathies;
2. Other diseases – renal or hepatic failure, diseases 
of the central nervous system, imflammatory 
or infectious diseases for the previous threee 
months, neoplastic or autoimmune diseases, 
chronic lung diseases, diseases of the endocrine 
system (except for diabetes mellitus type 2, 
noninsulin dependent, well controlled);
3. Intake of hormone replacement therapy, 
contraceptives, systemic intake of analgesics, 
including nonsteroid antiinflammatory drugs;
4. Impossibility for the patients to determine the 
onset of the arrhythmia;
5. Persistent rhythm disorder after the 24th hour 
scheme of propafenone; restoration of SR by 
means of electrical cardioversion; AF recur-
rences until the end of the study.
2. Obtaining erythrocytes and plasma 
In patients with PAF, blood samples were taken 
three times a day, immediately after hospitalization 
in the ward (baseline values), on the 24th hour and 
on the 28th day after the recovery of SR. The choice 
of the 28th day for the end of the monitoring was 
determined after the preliminary study conducted 
by us. The blood samples of the controls were taken 
once.
Plasma and erythrocytes were obtained from 
4 ml venous blood collected in a heparin vacutainer 
(Vacuette/4.0 ml/Li Hep). The blood was centrifuged 
at 4°C at 600 g for 10 min. The obtained plasma 
was removed from the erythrocytes and placed in 
a plastic test tube. Erythrocytes were washed twice 
with 0.9% sodium chloride and were centrifuged 
under the same conditions. The obtained erythro-
cyte suspension and plasma were frozen at -70ºС 
and stored at this temperature up to six months for 
biochemical analysis. 
3. Determination of MDA and GSH lev-
el in plasma and erythrocytes. GSH-Px activity 
determination
Lipid peroxidation was determined by the 
amount of thiobarbituric acid reactive substances 
formed in erythrocytes (31). Erythrocyte suspension 
(0.5%, according to Hb) in the presence and in the 




, as well as plasma (mg pro-
tein/ml), both in 0.15 M NaCl -10 mM sodium phos-
phate buffer, pH 7.2 were incubated for 60 minutes 
at 37oC. The absorbance was read at 532 nm against 
appropriate blanks; А
600
 was considered to be a non-
specific baseline and was subtracted from A
532
. Val-
ues were expressed in nmoles MDA per mg protein 
(for plasma) and in nmoles MDA per mg Hb (for 
erythrocytes), with a molar extinction coefficient of 
1.56x105M-1cm-1. 
Pl-GSH and Er-GSH were measured according 
to Tietze (32). The absorbance was read at 412 nm; 
values were expressed in ng/mg protein (for plasma) 
and ng/mg Hb (for erythrocytes), with glutathione 
oxidized (GSSG) as reference standard. 
GSH-Px activity in erythrocytes was mea-
sured by the method of Gunzler et al (33) and was 
expressed in nmoles NADPH oxidized per minute 
per mg Hb, with a molar extinction coefficient of 
6.22x106M-1cm-1.
Every sample was investigated three times, the 
obtained results having a high degree of repetitive-
ness (p>0.001); the mean value from the three mea-
surements was taken into consideration. The samples 
sent to the laboratory were coded which did not al-
lowed the researcher to have access to the informa-
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tion about the belonging of the sample (control or 
patient) or the date of its obtaining.
4. Statistical analysis of  the results.
The statistical processing of the results was 
performed by the GraphPad Prism 4 software. 
Descriptive statistics was used for the calculation of 
indicators for relative share, mean values, standard 
error of the mean (SEM) and central tendency (Mo). 
The analysis of hypotheses has been performed by 
means of Student’s t-criteria for comparing mean 
values and indicators of relative share at reliability 
level 0.95 (levels р<0.05 are considered statistically 
significant). All results were presented as a mean val-
ue ± SEM.
RESULTS
1. Patients’ characteristics 
The characteristics of the patients and the con-
trols are presented in Table 1. In terms of the indica-
tors for number, mean age and gender structure, the 
patients’ group was comparable to that of the con-
trol (р>0.05). In terms of the indicators for hyperten-
sion, diabetes mellitus, dyslipidemia and the admin-
istered treatment for them as well as those for cur-
rent smoking and alcohol intake, body mass index 
(BMI) and the measured echocardiographic indica-
tors, the group of patients with PAF was styatistically 
identical with that of the control group (р>0.05).
According to the data from the history taking, 
the mean duration of the AF episodes up to the time 
of hospitalization was 8.14±0.76 hours, the patients 
being most frequently hospitalized on the 5th hour 
from the onset of the arrhythmia (Mo=5 hours; 10 
patients out of all 51 patients). None of the patients 
was hospitalized after the 24th hour.
2. Levels of lipid peroxidation in the plasma 
and the erythrocytes 
Figure 1 shows that Pl-MDA levels upon 
admission to the ward were elevated as compared 
to those of the controls (0.143±0.007 vs 0.125±0.004 
nmol/mg protein, p<0.05). Twenty four hours after 
the restoration of SR, the measured values of Pl-
MDA were decreased and did not statistically differ 
from Pl-MDA levels of the controls (0.125±0.005 vs 
0.125±0.004 nmol/mg protein, p>0.05). Twenty-eight 
days after rhythm normalization, the results again 
showed lack of a significant difference with the con-
trols (0.117±0.004 vs 0.125±0.004 nmol/mg protein, 
p>0.05).
The results presented in Fig. 2 indicate elevated 
baseline values of Er-MDA levels in patients as com-
pared to the controls (1.368±0.069 vs 0.386±0.027 
nmol/mg Hb, p<0.001). Twenty four hours after 
recovery of SR Er-MDA values were significantly 
higher (0.916±0.047 vs 0.386±0.027 nmol/mg Hb, 
p<0.001). On the 28th day, the Er-MDA levels in 
patients did not statistically differ from the controls 
(0.419±0.039 vs 0.386±0.027 nmol/mg Hb, р>0.05).
3. Total GSH levels in plasma and erythrocytes
The patients‘ total Pl-GSH values upon hospi-
talization (Fig. 3) were lower as compared to those 
in the controls (64.97±1.28 vs 75.00±1.39 ng/mg pro-
tein, p<0.001). Measured twenty four hours after the 
restoration of SR, they continued to be significantly 
lower (68.78±1.32 vs 75.00±1.39 ng/mg protein, 
p<0.05). On the 28th day after the normalisation of 
the rhythm, Pl-GSH values in patients did not statis-
Fig. 1. Dynamics in Pl-MDA levels (nmol/mg protein) in 
patients with PAF
(* - р<0.05;  ns – statistically insignificant difference)
Fig. 2. Dynamics of Er-MDA levels (nmol/mg Hb) in 
patients with PAF
(**-p<0.001; * - р<0.05; ns – statistically insignificant 
difference)
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tically differ from those in the controls (73.96±1.93 vs 
75.00±1.39 ng/mg protein, р>0.05).
Baseline values of Er-GSH in patients with PAF 
(Fig. 4) were significantly decreased (997.00±32.60 
vs 1347.00±32.61 ng/mg Hb, p<0.001). Twenty four 
hours after rhythm regularization, they were still 
lower (1215.00±46.71 vs 1347.00±32.61 ng/mg Hb, 
p<0.05). On the twenty eight day, values of Er-GSH 
did not differ from that of the controls (1321.00±44.57 
vs 1347.00±32.61 ng/mg Hb, р>0.05).
4. Activity of GSH-Px in erythrocytes
Upon hospital admission, GSH-Px activity 
in erythrocytes (Fig. 5) was significantly decreased 
(25.00±0.81 vs 30.11±0.85 nmol/min/mg Hb, 
p<0.001). Twenty four hours after SR restoration, 
the lower enzyme activity persisted (27.20±1.04 vs 
30.11±0.85 nmol/min/mg Hb, p<0.05), while on the 
twenty eight day no significant difference was estab-
lished (30.72±0.67 vs 30.11±0.85 nmol/min/mg Hb, 
р>0.05).
Patients with PAF Control group
Number of participants in the group 51 52
Age (years) 59.84±1.60 59.50±1.46
Men/Women 26/25 26/26
Cardiovascular risk factors
Hypertension 37 (72.5%) 34(65.4%)
Diabetes mellitus type 2 3 (5.9%) 2(3.8%)
Dyslipidemia 4(7.8%) 3(5.8%)
Smoking* 8(15.7%) 7(13.5%)
Alcohol intake** 7 (13.7%) 6 (11.5%)
Body Mass Index (BMI) 23.85±0.46 kg/m² 24.95±0.45 kg/m²
Medicaments for Hypertension and Dyslipidemia
Beta blockers 19 (37.3%) 17(32.7%)
ACE inhibitors 15 (29.4%) 14(26.9%)
Sartans 11 (21.6%) 9(17.3%)
Statins 4 (7.8%) 3(5.8%)
Echocardiographic measurements 
LVEDD mm 52.57±0.58 52.29±0.57
LVEF% 62.98±0.70 61.54±0.58
LA volume ml/m² 22.81±0.45 23.82±0.48
LA: le! atrium; LVEF: le! ventricular ejection fraction: LVEDD: le! ventricular end-diastolic volume.
*"e smokers did not smoke more than half a packet weekly. "e hospitalized patients had not smoked minimum 24-48 hours before 
the onset of arrhythmia. "e investigations of the controls and those on the 28th day a!er dehospitalisation were performed a!er a 48-
hour period free of smoking.
**No more than 1-2 drinks/weekly. "e hospitalized patients had not consumed alcohol for a minimum of 48 hours before the onset of 
arrhythmia. "e investigations of the controls and those on the 28th day a!er dehospitalisation were performed a!er a 48-hour period 
without alcohol consumption.
Table 1. Characteristics of the patients with PAF and the controls
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DISCUSSION
The results from our study demonstrated that 
the values of all markers, measured upon patients’ 
admission to the ward, differ significantly from 
those of the controls (Fig. 1-5). MDA levels both in 
plasma and in erythrocytes were higher than those 
in the controls (Fig. 1, 2). As we have already men-
tioned MDA is one of the most common markers of 
lipid peroxidation. The elevated values provide in-
formation about enhanced oxidative damage of lip-
id biomolecules and are an indirect sign of increased 
levels of ROS (34,35). With these facts in mind, the 
results obtained by us give grounds to assume that 
early (still up to the 24th hour) in the clinical man-
ifestation of PAF, enhanced oxidative processes are 
present.
Baseline values of the investigated antioxidants 
also differed significantly from those measured in 
the controls (Fig. 3-5). The levels of total Er-GSH, 
Pl-GSH and the activity of GSH-Px in erythrocytes 
were considerable lowered. The total GSH in blood is 
a good indicator of oxidative status [19], its low val-
ues manifesting a lowered level of the nonenzyme 
antioxidant system. It is known that an early sign of 
a change in the oxidative balance is GSH-Px, its de-
creased activity being a manifestation of a reduced 
potential of the enzyme antioxidant system. There-
fore, our results for baseline values of Er-GSH, Pl-
GSH and GSH-Px indicated a decreased potential for 
eliminating ROS, respectively reduced antioxidant 
defense system.
Summarizing the results till now, we may 
conclude that still in the early hours (up to the 
24th hour) of AF clinical manifestation, disbalance 
of oxidative status is observed. Oxidative stress 
develops as a result of enhanced oxidative processes 
and reduced defense antioxidant mechanisms. The 
early manifestation of these disorders enables us to 
assume that they are most likely associated with the 
initiation of AF. 
The oxidative status in PAF has been subject to 
other studies, too. Wy et al. established significant-
ly increased levels of serum MDA and reduced ac-
tivity of superoxide dismutase (36). The fact must be 
noted that these changes in oxidative status, unlike 
our results, were registered in much later hours from 
the onset of the disease – up to the seventh day. Con-
siderably greater in number are experimental stud-
ies. Pacing of in vitro differentiated cardiomyocytes 
caused a significant decrease in intracellular contents 
of thioles (9). The induction of arrhythmia in exper-
imental models led to a decrease in ascorbate level 
and elevation of 3-Nitrotyrosine in the atrial tissue 
[8], increased production of superoxide onions (37), 
up-regulation of NADPH oxidases (Nox 2/4) and 
Rac1 (7,38). In essence, these results are extremely 
important but as it is known that the condition in the 
experimental models are not identical with those in 
the human organism.
Fig. 3. Dynamics in Pl-GSH levels (ng/mg protein) in 
patients with PAF
(**-p<0.001; * - р<0.05;  ns – statistically insignificant 
difference)
Fig. 4. Dynamics in Er-GSH levels (ng/mg protein) in  
patients with PAF
(**-p<0.001; * - р<0.05;  ns – statistically insignificant 
difference)
Fig. 5. Dynamics in GSH-Px activity (nmol/min/mg Hb) 
in erythrocytes in patients with PAF.
(**-p<0.001; * - р<0.05;  ns – statistically insignificant 
difference)
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The results obtained 24 hours after the arrhyth-
mia discontinuation are specific in their nature. The 
values of four out the five studied markers still dif-
fered statistically from those in the controls – lev-
els of Er-MDA were still significantly higher (Fig. 2) 
and the values of Pl-GSH, Er-GSH and GSH-Px re-
mained low (Fig. 3-5). In spite of the restored SR, pro-
cesses of lipid peroxidation in erythrocytes remained 
enhanced and antioxidant defense system – with 
lowered activity. The persistence in these changes 
leads us to the conclusion that the oxidative status of 
patients with PAF is disordered not only during the 
clinical manifestation of arrhythmia but also after-
wards. The impact of enhanced oxidative processes 
on the organism and on the cardiovascular system 
in particular continues after the arrhythmia episode, 
too. A number of studies have demonstrated a pos-
sible relation between oxidative status and structur-
al remodeling of the atria (39-44). Data are available 
confirming that atrial remodeling is associated with 
the manifestation and the retention of AF (45-47). 
Consequently, the persistence of changes in oxida-
tive status established by us after the recovery of SR 
are very important for the clinical course of AF and 
are most likely related to the arrhythmia recurrences.
Noteworthy, Pl-MDA values did not differ sta-
tistically from those in the control group (Fig. 1), un-
like the values of the same marker measured in the 
erythrocytes (Fig. 2). This result could be explained 
with the fact that erythrocytes are more susceptible 
to oxidative damage due to high contents of polyun-
saturated fatty acids in their cell membrane and in-
creased concentration of oxygen (48,49).
The results obtained 28 days after SR recovery 
are particularly interesting. Between patients and 
controls there was no statistically significant differ-
ence in any of the investigated markers (Fig. 1-5). The 
analysis of these results indicates that oxidative bal-
ance in the patients’ group was restored. A decrease 
was observed in the activity of prooxidant system 
(Fig. 1, 2) and elevated levels of the antioxidant de-
fense system (Fig. 3-5) during the studied period fol-
lowing SR recovery. These processes occur relative-
ly slowly in time (up to the 28thday) which predeter-
mines the continuous effect of the enhanced oxida-
tive processes on the organism. 
It is noteworthy that during the period of the 
study, in the patients with PAF was initiated no treat-
ment with medications that influence oxidative sta-
tus of the organism. This is an argument for us to 
consider that the restoration of oxidative balance is 
a result of endogenous regulatory mechanisms such 
as the involvement of the endocrine system (50). As 
far as in the course of our study disorders in prooxi-
dant and antioxidant system were present, we are of 
the opinion that their simultaneous therapeutic in-
fluence is expedient. 
CONCLUSION
In conclusion, the oxidative stress develops 
still in the early (up to 24thhour) of PAF, with 
simultaneously significantly increased prooxidant 
activity and decreased levels of antioxidant defense 
system. These changes persist after the recovery of 
SR and oxidative balance is restored gradually with 
time. This specific dynamics in oxidative status is 
probably closely related to the clinical course of the 
disease, namely to its manifestation and recurrences. 
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